Cargando…
Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
BACKGROUND: We recently reported that self‐evaluation of the incidence and severity of treatment‐related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0‐based questionnaire was feasible and more informative than doctor reports i...
Autores principales: | Galizia, Danilo, Milani, Andrea, Geuna, Elena, Martinello, Rossella, Cagnazzo, Celeste, Foresto, Manuela, Longo, Virginia, Berchialla, Paola, Solinas, Gianfranca, Calori, Adele, Grasso, Bruna, Volpone, Chiara, Bertola, Gisella, Parola, Gisella, Tealdi, Giancarla, Giuliano, Piero Luigi, Ballari, Anna Maria, Aglietta, Massimo, Montemurro, Filippo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144000/ https://www.ncbi.nlm.nih.gov/pubmed/30030895 http://dx.doi.org/10.1002/cam4.1687 |
Ejemplares similares
-
Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020) -
Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015) -
The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021) -
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010) -
Adoptive immunotherapy against ovarian cancer
por: Mittica, Gloria, et al.
Publicado: (2016)